We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Optimized Gold Nanoparticles to Improve Drug Delivery, Cancer Therapy and Imaging

By MedImaging International staff writers
Posted on 04 Jun 2025
Image: Optimizing gold nanoparticles can improve medical imaging, drug delivery, and cancer therapy (Photo courtesy of Shutterstock)
Image: Optimizing gold nanoparticles can improve medical imaging, drug delivery, and cancer therapy (Photo courtesy of Shutterstock)

Health care professionals utilize gold nanoparticles for a variety of medical purposes, including diagnostic imaging and cancer treatment. Gold is an ideal material for these applications due to its biocompatibility, stability, and visibility in imaging tests. However, despite the wide use of gold nanoparticles in medicine, there is limited understanding of how their size influences their performance. L-cysteine, an amino acid crucial in many biological functions, can prevent gold nanoparticles from aggregating, which is essential for ensuring the success of medical treatments. By forming a strong bond with gold, L-cysteine facilitates the attachment of nanoparticles to specific targets, such as cancer cells. A new study aimed at exploring the relationship between the size of gold nanoparticles and their interaction with L-cysteine found that smaller nanoparticles tend to exhibit the best performance.

Researchers at Western University (London, ON, Canada) collaborated with the Canadian Light Source at the University of Saskatchewan (Saskatoon, SK, Canada) to investigate how the size of gold nanoparticles affects their interaction with L-cysteine. Using synchrotron light along with other advanced techniques, the team found that smaller gold nanoparticles (5 nanometers) formed stronger bonds with L-cysteine compared to larger nanoparticles (10, 15, and 20 nanometers). For context, a human hair is approximately 100,000 nanometers wide.

The findings, published in the journal Particle & Particle Systems Characterization, also revealed that the smallest gold nanoparticles were less likely to clump together when L-cysteine was present. Clumping can impair the effectiveness, stability, and safety of nanoparticles. The researchers believe that these insights could help optimize the size of gold nanoparticles, thereby enhancing drug delivery, improving cancer treatment, and refining imaging techniques.

“It is important to know if the (gold) particle stays the same size, because each size has specific properties and you design the particle in this way, and then don't want it to change in the human body,” said Yolanda Hedberg, a professor of chemistry at Western University. “When we understand exactly how the size is affecting the reaction with the environment, we can design the particle size in a way that we make the nanomedicine as effective as possible.”

High-Precision QA Tool
DEXA Phantom
Digital Radiography System
DR-300
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Post-Processing Imaging System
DynaCAD Prostate

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.